Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

Effect of Sitagliptin on Clinical, Metabolic and Hormonal Parameters in Polycystic Ovarian Syndrome Patients

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05972928

Enrollment

Registered

2023-08-02

Start date

2023-07-30

Completion date

2023-10-30

Last updated

2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

Polycystic Ovary Syndrome, Sitagliptin

Brief summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility

Detailed description

Study Design : a Prospective Randomized Controlled Trial. A Total of 80 infertile Adult Females aged between 18 and 45 years currently diagnosed with Polycystic ovary syndrome , Meeting the Diagnosis of Rotterdam criteria be diagnosed if any two of the following are present: (1) clinical or biochemical hyperandrogenism, (2) evidence of oligo-anovulation, (3) polycystic appearing-ovarian morphology on ultrasound are to be included in the study. The study will include two groups; each group consists of 40 patients:- Group A : Control Group Group B : Test Group ( will Receive Sitagliptin at a dose of 100 mg every 24 hours

Interventions

DRUGSitagliptin 100mg

Sitagliptin at a dose of 100 mg every 24 hours for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present: 1. oligo- and/or anovulation 2. hyperandrogenism (HA) (clinical and/or biochemical) 3. polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3).

Exclusion criteria

1. congenital adrenal hyperplasia 2. Brittle control of a thyroid disorder 3. Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance 4. chronic kidney disease 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption

Design outcomes

Primary

Measure	Time frame	Description
Body weight loss in Kilograms	3 months	Body weight before - Body weight after

Countries

Egypt

Contacts

Primary ContactBeni-suef University

fom@med.bsu.edu.eg082 2318605

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026